Literature DB >> 2033257

Cathepsin B cleavage of Ii from class II MHC alpha- and beta-chains.

V E Reyes1, S Lu, R E Humphreys.   

Abstract

Class II MHC-associated invariant chain (Ii) might regulate binding of digested peptides to the Ag binding site (desetope) of class II MHC proteins by directly or allosterically blocking that site until cleavage and release of Ii from MHC alpha- and beta-chains at the time of peptide charging. We examined the cleavage and release of Ii from class II MHC alpha/beta Ii trimers by cathepsin B, which has been shown by others to colocalize with class II MHC molecules in intracellular compartments and to generate antigenic peptide fragments. Cathepsin B at pH 5.0 cleaved and released Ii from class II MHC alpha- and beta-chains. Cathepsin B digested Ii from alpha- and beta-chains in a dose-dependent fashion, yielding 23-, 21-, and 10-kDa fragments. Blockage of cathepsin B activity with leupeptin restored the 2D(nonequilibrium pH gradient gel electrophoresis/SDS) PAGE patterns of Ii and sialic acid-derivatized forms of Ii seen without the protease. The fragmentation pattern of cathepsin D treatment was different from that of cathepsin B, yielding 25-kDa intermediates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033257

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Polarized expression of CD74 by gastric epithelial cells.

Authors:  Carlos A Barrera; Ellen J Beswick; Johanna C Sierra; David Bland; Rosario Espejo; Randy Mifflin; Patrick Adegboyega; Sheila E Crowe; Peter B Ernst; Victor E Reyes
Journal:  J Histochem Cytochem       Date:  2005-05-27       Impact factor: 2.479

2.  Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1.

Authors:  S J Park; S Sadegh-Nasseri; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 3.  Immune evasion strategies used by Helicobacter pylori.

Authors:  Taslima T Lina; Shatha Alzahrani; Jazmin Gonzalez; Irina V Pinchuk; Ellen J Beswick; Victor E Reyes
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

4.  Mononuclear phagocyte hydrolytic enzyme activity associated with cerebral HIV-1 infection.

Authors:  B B Gelman; D A Wolf; M Rodriguez-Wolf; A B West; A K Haque; M Cloyd
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

5.  Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.

Authors:  Kaoru Saegusa; Naozumi Ishimaru; Kumiko Yanagi; Rieko Arakaki; Kouichi Ogawa; Ichiro Saito; Nobuhiko Katunuma; Yoshio Hayashi
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 6.  CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract.

Authors:  Ellen J Beswick; Victor E Reyes
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

7.  Cathepsin S activity regulates antigen presentation and immunity.

Authors:  R J Riese; R N Mitchell; J A Villadangos; G P Shi; J T Palmer; E R Karp; G T De Sanctis; H L Ploegh; H A Chapman
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

8.  Discordant Expression of Ii and HLA-DR in Thyrocytes: A Possible Pathogenetic Factor in Hashimoto's Thyroiditis.

Authors:  Mujun Yu; Mingzhen Xu; Lou Savas; Ashraf Khan
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

9.  Stable surface expression of invariant chain prevents peptide presentation by HLA-DR.

Authors:  P A Roche; C L Teletski; D R Karp; V Pinet; O Bakke; E O Long
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

10.  Alteration of a single hydrogen bond between class II molecules and peptide results in rapid degradation of class II molecules after invariant chain removal.

Authors:  S Ceman; S Wu; T S Jardetzky; A J Sant
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.